Arch Oncology: Funding, Investors & Team (Sep 2026)
At Arch Oncology, they are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. They are committed to advancing antibodies with best-in-class potential.Their next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
Arch Oncology has raised $105M across 1 funding round on record, the most recent a Series C of $105M announced in Apr 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Arch Oncology Company Profile and Key Stats
Latest funding round on record: Apr 2021.
Arch Oncology Funding Rounds
Arch Oncology Founders and Leadership Team
Contact details for the Arch Oncology team: 1 of 1 has an email address on file.
Start 14-day free trial →Arch Oncology Funding Compared to Other Biotechnology Startups
Arch Oncology's latest round of $105M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Arch Oncology in Biotechnology and Brisbane
Companies Similar to Arch Oncology
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Arch Oncology Funding FAQs
What does Arch Oncology do?
At Arch Oncology, they are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. They are committed to advancing antibodies with best-in-class potential.Their next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
How much funding has Arch Oncology raised?
Arch Oncology has raised $105M across 1 round on record. The most recent is a Series C of $105M announced in Apr 2021.
When did Arch Oncology last raise funding?
Arch Oncology's most recent funding round on record is a Series C of $105M, announced in Apr 2021.
Who is the CEO of Arch Oncology?
Laurence Blumberg is listed as CEO at Arch Oncology.
Where is Arch Oncology headquartered?
Arch Oncology is based in Brisbane, California, United States.
How many employees does Arch Oncology have?
Arch Oncology is in the 11-50 employee band.
How does Arch Oncology's funding compare to other Biotechnology startups?
Arch Oncology's latest round of $105M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Arch Oncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Arch Oncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.